[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-allergy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-allergy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,58,85,108,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100547295","phase-2-optimizing-the-diagnostic-approach-to-cephalosporin-allergy-testing-100547295",false,"NCT06406114","Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","DACAT","Inclusion Criteria:\n\n1. Age 18-70 years old.\n2. Reaction history consistent with a potential immediate hypersensitivity reaction (pruritus, urticaria, erythema, angioedema, bronchospasm, wheezing, shortness of breath, anaphylaxis, or hypotension) to cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime.\n3. English speaking or non-English speaking with translation services available.\n\nExclusion Criteria:\n\n1. Severe concomitant medical condition (e.g., unstable coronary artery disease, congestive heart failure, severe chronic obstructive pulmonary disease, poorly controlled asthma, chronic renal failure, cirrhosis, or end-stage liver disease.)\n2. History of Clostridioides difficile infection\n3. Chronic spontaneous urticaria or systemic mastocytosis\n4. Incident reaction required cardiopulmonary resuscitation\n5. Reaction to 2 or more cephalosporin antibiotics\n6. Active infection or antibiotic treatment within 7 days\n7. Treatment with systemic antihistamines or corticosteroids within 7 days\n8. Treatment with omalizumab or dupilumab within 60 days\n9. Significant immunosuppression\n10. Treatment with a beta-blocker or ACE inhibitor within 7 days\n11. Use of investigational drugs within 60 days of participation\n12. Anaphylaxis in the last 30 days\n13. Penicillin anaphylaxis within the past year confirmed with positive penicillin skin tests\n14. Prison or jail inmates, pregnant women, severe cognitive impairment\n15. Current, diagnosed, mental illness or current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements\n16. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n17. Inability or unwillingness of a participant to give written informed consent or comply with study protocol","ALL","18 Years","70 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.",[27,28,29,30,31,32,33],"Drug Allergy","Cephalosporin Allergy","Drug Hypersensitivity","Antibiotic Allergy","Beta Lactam Adverse Reaction","Drug-Induced Anaphylaxis","Cephalosporin Reaction",[35,36,37,38,39,40,41,42,43,44],"Allergy","Antibiotic","Cephalosporin","Penicillin","Beta-lactam","Drug challenge","Skin testing","Adverse reaction","Anaphylaxis","Perioperative anaphylaxis","RECRUITING","2026-05-22",{"date":48,"type":49},"2026-05-26","ACTUAL",{"date":51,"type":49},"2025-05-05",{"date":53,"type":21},"2028-12-31",{"name":55,"class":56},"Massachusetts General Hospital","OTHER",6,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100602770","provocation-after-nurse-directed-assessment-panda-study-100602770","NCT07127835","Provocation After Nurse-Directed Assessment (PANDA) Study","PANDAS","Inclusion Criteria:\n\n* Receiving inpatient or outpatient treatment at a participating hospital during the study period;\n* Possessing a documented penicillin allergy label;\n* Underwent penicillin allergy evaluation by the nurse-allergist collaborative approach or the traditional allergist-led approach\n* Demographic and clinical data required for the study available.\n\nExclusion Criteria:\n\n* Patients unable to provide a complete medication history or history of penicillin allergy;\n* Patients with only emergency or short-term treatment records;\n* Patients who have taken steroids, antihistamines, or similar medications within the last 3 days.",{"count":66,"type":21},440,"OBSERVATIONAL","The study aims to evaluate the effectiveness and safety of a collaborative nurse-allergist approach in penicillin allergy delabeling services. It also seeks to assess the impact on patients' quality of life and compare resource utilization and cost-effectiveness between the nurse-allergist collaborative approach and the traditional allergist-led approach.",[27,70],"Penicillin Allergy",[72,73,74],"Nurse-led Service","Drug Provocation Test","Delabelling","2026-04-28",{"date":77,"type":49},"2026-04-29",{"date":79,"type":49},"2025-09-01",{"date":81,"type":21},"2029-08-31",{"name":83,"class":56},"The University of Hong Kong",4,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":35,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100593805","in-search-of-the-correct-diagnosis-of-beta-lactam-allergy-from-the-validation-of-a-risk-stratification-tool-to-accurate-endotyping-100593805","NCT07011212","In Search of the Correct Diagnosis of Beta-lactam Allergy: From the Validation of a Risk Stratification Tool to Accurate Endotyping","Inclusion Criteria:\n\n* signed informed consnet\n\nExclusion Criteria:\n\n* Use of immunomodulators, antihistamines and corticosteroids","14 Years",{"count":93,"type":21},332,[95],"NA","Testing a clinical decision tool (BL-Predictor)",[27],"NOT_YET_RECRUITING","2025-05-30",{"date":101,"type":49},"2025-06-08",{"date":103,"type":21},"2025-07",{"date":105,"type":21},"2027-07",{"name":107,"class":56},"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100577858","teicoplanin-allergy-testing-using-autologous-serum-tatas-100577858","NCT06803758","Teicoplanin Allergy Testing Using Autologous Serum (TATAS)","Improving The Sensitivity of Teicoplanin Allergy Testing By Using Autologous Serum","TATAS","Inclusion Criteria:\n\n* Adult patients 18 years old and above who have suffered suspected anaphylaxis under anaesthesia (the 'index episode'), where teicoplanin has been given\n\nExclusion Criteria:\n\n* Patients unable to stop drugs that would interfere with skin tests prior to study- e.g. antihistamines or certain anti-psychotics\n* Pregnancy\n* Patients under age 18 years\n* Patients with elevated baseline mast cell tryptase requiring further investigation\n* Patients with blood-borne viruses such as Hep B, C and HIV",true,{"count":118,"type":21},20,[95],"Allergy testing for Teicoplanin is much more unreliable than for other similar drugs. This means that we run the risk of missing serious Teicoplanin allergy, and these patients will be given another dose in future, not knowing that they are seriously allergic. Serious allergic reactions, also known as anaphylaxis, can be life threatening.\n\nThe patients which we recruit to our study will come to us through the perioperative allergy service. They will have had a reaction to a general anaesthetic, but will also have had teicoplanin as part of the anaesthetic.\n\nWe are not sure why allergy skin testing, which is fairly reliable for most other drugs, is so unreliable in detecting teicoplanin allergy. We do know that some drugs need to mix with proteins in the blood before they trigger an allergy. We would like to replicate this by mixing the teicoplanin with the patients' own blood and using this for the skin testing, to see if we get a more reliable result compared with the plain drug. Using the patient's own serum to do skin testing is an established test (the 'autologous serum test') used in certain immunological conditions, we are simply going to use it as a vehicle to test our theory.\n\nWe will recruit 20 adult patients referred with a recent history of anaphylaxis under anaesthesia, where teicoplanin has been given and is one of the drugs under suspicion of having caused the allergy. In addition to the usual allergy skin testing, which would be done anyway as part of standard allergy investigation, we will perform extra tests using autologous serum for this trial.\n\nWe hope to find a better way of testing for Teicoplanin allergy, so that patients are not put at risk where the allergy has been missed because of an unreliable test.",[27],[123,124],"Teicoplanin allergy testing","Autologous Serum","2025-01-27",{"date":127,"type":49},"2025-01-31",{"date":129,"type":49},"2025-01-08",{"date":131,"type":21},"2026-12",{"name":133,"class":56},"University Hospital Southampton NHS Foundation Trust",1,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":116,"sex":16,"minAge":142,"maxAge":17,"enrollmentInfo":143,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":134},"100502326","high-dimensional-analysis-of-immune-cells-in-pediatric-patients-100502326","NCT05820802","High Dimensional Analysis of Immune Cells in Pediatric Patients","High Dimensional Analysis of Immune Cells Using scRNA-seq in Pediatric Patients With Allergic Reactions to Neuromuscular Blockers","Inclusion Criteria:\n\n* Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium.\n\nExclusion Criteria:\n\n* Patients who have received immunomodulators, immunosuppressants, etc.\n* Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.)\n* Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.)\n* Other cases where the Principal Investigator determines that it is difficult to conduct the study.","2 Years",{"count":144,"type":21},294,"The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.",[27,147],"Neuromuscular Blockade","2024-11-26",{"date":150,"type":49},"2024-11-29",{"date":152,"type":49},"2023-04-27",{"date":154,"type":21},"2026-12-01",{"name":156,"class":56},"Seoul National University Hospital"]